---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-001032"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:17:12.758516+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Edgewise reports Q2 net loss $0.32/sh; positive EDG-5506 BMD interim data

## Summary
- Cash and equivalents $248.4M as of June 30; expected to fund operations through end of 2024.
- Net loss $16.1M ($0.32/sh) for Q2 2022 vs $14.7M ($0.30/sh) prior quarter.
- ARCH study: CK reduced 30%, TNNI2 reduced 68% after 2 months of EDG-5506 10 mg daily.
- Enrolling CANYON Phase 2 trial of EDG-5506 in BMD; plan to start Phase 2 in DMD in 2022.
- Preclinical EDG-002 program for HCM advancing; IND-enabling studies planned in 2022.

## SEC filing metadata
- accession: 0001157523-22-001032
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000115752322001032/0001157523-22-001032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000115752322001032/a52801668.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-001032
- JSON: https://secwatch.observer/filing/0001157523-22-001032.json
- Plain text: https://secwatch.observer/filing/0001157523-22-001032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.